Tesamorelin (Egrifta): The One Growth-Hormone Peptide With an Approved Indication
Tesamorelin, marketed as Egrifta, is a growth-hormone-releasing factor analogue approved for a specific indication: reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general weight loss, body composition or anti-ageing, and it is not comparable to a GLP-1 in either mechanism or evidence base.
What it is approved for, and what it is not
| Claim | Status |
|---|---|
| Reduces excess visceral abdominal fat in HIV-associated lipodystrophy | Approved indication |
| General weight loss | Not an approved indication |
| Body recomposition in healthy adults | Not studied for this |
| Anti-ageing or longevity | Not an approved indication; not established |
| Athletic performance | Not an approved indication |
The gap between row one and rows two to five is where most online marketing operates.
Labelled risks worth knowing before anything else
- Glucose intolerance and diabetes. Growth hormone axis stimulation can worsen glycaemic control, which is the most clinically significant labelled concern.
- Injection-site reactions, commonly reported.
- Fluid retention, joint pain and peripheral oedema, consistent with growth-hormone effects.
- Malignancy considerations. Labelling addresses active malignancy; this is a prescriber's assessment.
- Hypersensitivity reactions, reported.
Effects reverse on discontinuation, as with the GLP-1s. Visceral fat reduction is not maintained after stopping.
Where it sits against the rest of this category
| Peptide | Approved indication | Human efficacy trials |
|---|---|---|
| Semaglutide | Yes — diabetes and weight management | Multiple phase 3 |
| Tirzepatide | Yes — diabetes, weight, sleep apnoea | Multiple phase 3 |
| Liraglutide | Yes — with approved generics | Multiple phase 3 |
| Tesamorelin | Yes — one specific indication | Yes, in that population |
| Sermorelin | Was approved; withdrawn commercially | Limited |
| Ipamorelin | No | Limited |
| BPC-157 | No — Category 2 bulks list | None |
Tesamorelin is genuinely evidenced — within its indication. That qualifier is the whole point.
What to ask if it has been suggested to you
- Which indication is this being prescribed for? If not HIV-associated lipodystrophy, it is off-label, and the trials do not cover it.
- How will glucose be monitored? The most significant labelled concern.
- Is this the approved product or a compounded preparation? Different questions follow.
- What happens on stopping? The effect is not maintained.
How growth-hormone-axis peptides get marketed
A recognisable pattern runs through this corner of the market, and tesamorelin is the legitimate product that gets used to lend it credibility.
- A real mechanism — the growth-hormone axis genuinely affects body composition.
- A real approved product — tesamorelin, approved for one indication.
- An unapproved analogue — ipamorelin, sermorelin, or a blend, presented as working "the same way".
- An implied transfer of evidence that was never established for the analogue.
Steps one and two are true. Step four is where the argument fails, and it usually happens without being stated outright.
| Tesamorelin | Sermorelin | Ipamorelin | |
|---|---|---|---|
| Approved indication | Yes, one | Withdrawn commercially | No |
| Human efficacy trials in that indication | Yes | Limited | Limited |
| Evidence transfers from tesamorelin | — | No | No |
| Labelled safety profile | Yes | Historic | No |
Sharing a mechanism is not sharing an evidence base.
The monitoring question
Because the most significant labelled concern is glucose intolerance, any legitimate prescribing of a growth-hormone-axis peptide involves baseline and ongoing glycaemic monitoring. A programme that does not mention monitoring is a signal in itself — not because monitoring is a formality, but because it is the specific thing the labelling flags.
What this page does not settle
- Whether tesamorelin helps outside its approved indication. Not studied for that.
- Whether analogues do anything useful. No human efficacy trials establish it.
- Long-term safety in healthy adults. The trials were in a specific patient population.
Indicative count of registered phase 2/3 trials with a published efficacy endpoint in the relevant indication, compiled 4 August 2026. Tesamorelin's are within HIV-associated lipodystrophy, not general fat loss.
Why this peptide is worth understanding even if it is not for you
Tesamorelin is the clearest available demonstration that "approved" is always approved for something. It is a genuine, evidenced, FDA-approved product — and almost none of the online marketing that invokes it is describing the population it was approved for.
That pattern generalises. When any product is described as approved, the useful follow-up is not whether but for what, and whether that matches your situation. It is a one-sentence check that resolves a large share of the claims in this market.
What this page does not settle
- Whether tesamorelin is appropriate for you. That is a prescriber's assessment against an approved indication.
- Whether compounded versions match the approved product. No trial has tested one.
- Anything about analogues. Sharing a mechanism is not sharing an evidence base.
Common questions
Can tesamorelin be used for general weight loss?
It is not approved for that and was not studied for it. Its trials were in adults with HIV-associated lipodystrophy, measuring visceral abdominal fat in that population. A result in one population does not transfer to another, which is the single most common error in how this product is marketed.
Is it safer than a GLP-1?
They are not comparable on that axis, and neither is a general-purpose safety ranking. Tesamorelin's most significant labelled concern is glucose intolerance and worsening glycaemic control. The GLP-1s carry their own labelled risks, including a boxed warning based on rodent thyroid C-cell findings. Both require a prescriber's assessment against your history.
What about sermorelin and ipamorelin?
Sermorelin was approved and withdrawn for commercial rather than safety reasons, so products sold today are compounded preparations rather than a current approval. Ipamorelin has no approved indication and limited human data. Neither inherits tesamorelin's evidence by sharing a mechanism.
Why does this peptide appear on GLP-1 comparison sites at all?
Because it is a peptide that affects body composition and has an FDA approval, which makes it the most credible-looking item in a category where most items have no trials. Grouping by chemical class puts it beside BPC-157; grouping by evidence puts it beside the GLP-1s in kind but not in scope, because its evidence covers one condition in one population. The second grouping is the one a reader needs.
Does the effect last?
No. Visceral fat reduction is not maintained after discontinuation, which puts it in the same category as the GLP-1s on that point: an ongoing treatment rather than a course.